L-Methylfolate Prescription Guidelines

Primary Indications for L-Methylfolate

Patients with MTHFR 677TT genotype should receive L-methylfolate rather than folic acid because they cannot efficiently convert folic acid to its biologically active form 1, 3
The MTHFR C677T polymorphism is particularly common in certain populations, with the inactive T allele showing variable distribution across ethnic groups 4
Patients with elevated homocysteine levels and MTHFR 677TT genotype benefit specifically from L-methylfolate rather than standard folic acid 4, 1
Target homocysteine levels should be <10 μmol/L for optimal cardiovascular protection 4

For neural tube defect prevention in women of childbearing age without MTHFR polymorphisms, standard folic acid 400 μg daily remains first-line 5, 6, 2
Women with prior neural tube defect pregnancy require 4 mg folic acid daily starting 3 months preconception 2
Standard folic acid has nearly twice the bioavailability of food folate and is more cost-effective than L-methylfolate for routine supplementation 1
Dietary folate deficiency should be treated with standard folic acid 1-5 mg daily for 4 months 7, 6, 2
Maintenance dosing after correction is 330 μg daily for adults, 600 μg for pregnant/lactating women 7, 2

Always assess B12 status before initiating any folate supplementation to avoid masking B12 deficiency while neurological complications progress 7, 6, 2
Both biochemical B12 deficiency and metabolic B12 deficiency are common in stroke patients 4
Folate supplementation can improve hematologic parameters while neurological manifestations of B12 deficiency worsen 7
The upper limit for unsupervised folic acid is 1 mg/day specifically to prevent delayed diagnosis of B12 deficiency 7, 6
Methotrexate users should receive standard folic acid, not L-methylfolate, as folic acid is equally effective at lower cost 2

Folinic acid must be used—never folic acid or L-methylfolate—during pyrimethamine therapy for toxoplasmosis at 10-20 mg daily 8, 1
Folinic acid is required for methotrexate rescue therapy 1
Patients with malabsorption or oral intolerance require parenteral administration: 0.1 mg/day subcutaneously, intravenously, or intramuscularly 2
Inflammatory bowel disease patients on sulfasalazine/methotrexate require prophylactic supplementation, typically 1-5 mg folic acid daily 2

Measure serum/plasma folate and red blood cell folate at baseline and 3 months after supplementation 7, 6, 2
Homocysteine measurement improves interpretation of folate status 7, 6, 2
For conditions increasing folate needs, monitor every 3 months until stabilization, then annually 7, 2